April MIMS update

Some of the recent changes to the medicines landscape, with new products and indications New Products Fedratinib (as dihydrochloride monohydrate) (Inrebic) is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase (JAK) 2 and FMS-like tyrosine kinase 3 (FLT3). Fedratinib is a JAK2-selective inhibitor with higher inhibitory activity for